Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

55 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: National Cancer Institute (NCI)
Termination share: 19.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	withdrawn	Phase 2	0	Fred Hutchinson Cancer CenterOTHER	1	Jun 30, 2021	clinicaltrials
NCT03365661	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	withdrawn	Phase 2	0	Masonic Cancer Center, University of MinnesotaOTHER	1	Nov 9, 2018